Geneva, June 20 -- International Clinical Trials Registry received information related to the study (NCT07012057) titled 'Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis' on June 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Condition:
Myositis
Dermatomyositis
Intervention:
Drug: Deucravacitinb
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 18, 2025
Target Sample Size: 20
Countries of Recruitment:
United States
To know more, visit https...